Abstract: An NK cells and PBMC, both having increased cytotoxicity are provided. Particularly, NK cells and PBMC which have exogenous mitochondria introduced thereinto potentiate the immune system of the human body to enhance a therapeutic effect on infectious diseases or cancer. Therefore, the NK cells and PBMC can be used in a composition for prevention or treatment of infectious diseases and cancer. Specially, autogenous NK cells and PBMC guarantee stability without the incurrence of an immune reaction, and thus would be expected to have high commercial activity.
Abstract: An NK cells and PBMC, both having increased cytotoxicity are provided. Particularly, NK cells and PBMC which have exogenous mitochondria introduced thereinto potentiate the immune system of the human body to enhance a therapeutic effect on infectious diseases or cancer. Therefore, the NK cells and PBMC can be used in a composition for prevention or treatment of infectious diseases and cancer. Specially, autogenous NK cells and PBMC guarantee stability without the incurrence of an immune reaction, and thus would be expected to have high commercial activity.
Abstract: The present invention relates to a pharmaceutical composition containing mitochondria and, more specifically, to a pharmaceutical composition for preventing or treating muscle diseases or ischemic diseases, containing mitochondria as active ingredients. The pharmaceutical composition of the present invention contains heterologous mitochondria or cells comprising heterologous mitochondria, thereby enabling the mitochondrial activity of cells to which the same is administered to improve. Therefore, the pharmaceutical composition according to the present invention can be useful in the fundamental prevention or treatment of muscle diseases or ischemic diseases, which occur in relationship with the deterioration of mitochondrial function.
Type:
Application
Filed:
November 28, 2017
Publication date:
January 9, 2020
Applicant:
PAEAN BIOTECHNOLOGY INC.
Inventors:
Yong-Soo CHOI, Chang-koo YUN, Mi-Jin KIM, Jung Uk HWANG
Abstract: The present invention relates to a method for delivering exogenous mitochondria into cells and, more specifically, to a method for efficiently delivering, into the cytoplasm of target cells to be injected, mitochondria isolated from donor cells.
Type:
Application
Filed:
November 14, 2017
Publication date:
September 12, 2019
Applicant:
PAEAN BIOTECHNOLOGY INC
Inventors:
Yong-Soo CHOI, Chang-koo YUN, Min-Jin KIM, Jung Uk HWANG, Chun-Hyung KIM, Youngjun LEE
Abstract: An NK cells and PBMC, both having increased cytotoxicity are provided. Particularly, NK cells and PBMC which have exogenous mitochondria introduced thereinto potentiate the immune system of the human body to enhance a therapeutic effect on infectious diseases or cancer. Therefore, the NK cells and PBMC can be used in a composition for prevention or treatment of infectious diseases and cancer. Specially, autogenous NK cells and PBMC guarantee stability without the incurrence of an immune reaction, and thus would be expected to have high commercial activity.
Abstract: The present invention relates to a microneedle, to a mould for producing same, and to a production method for same. More specifically, the present invention concerns a microneedle for causing a skin-beautifying substance or drug to be absorbed via the skin, to a plastic mould for producing same, and to a production method for same.
Type:
Application
Filed:
January 21, 2014
Publication date:
December 10, 2015
Applicants:
BUKYOUNG PHARM CO.,LTD., PAEAN BIOTECHNOLOGY INC., MITI SYSTEMS INC